UCLA Health

Belkins
For more than half a century, UCLA Health has provided the best in healthcare and the latest in medical technology to the people of Los Angeles and throughout the world. Comprised of Ronald Reagan UCLA Medical Center, UCLA Medical Center Santa Monica, Resnick Neuropsychiatric Hospital at UCLA, UCLA Mattel Children's Hospital, and the UCLA Medical Group with its wide-reaching system of primary-care and specialty-care offices throughout the region, UCLA Health is among the most comprehensive and advanced healthcare systems in the world.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MEDTECH

OCHRE BIO ENTERS INTO CHARITABLE DONATION AGREEMENT WITH BRITISH LIVER TRUST

Ochre Bio | December 15, 2021

news image

Ochre Bio, a biotech company developing RNA medicines for chronic liver diseases, announced to have entered into a Charitable Donation Agreement with the British Liver Trust in support of improving awareness for liver health. “On our path to develop next-generation RNA medicines with the potential to improve the lives of patients in need of a liver transplant, we are grateful to have access to discarded donor livers, allowing us to develop therapeutics that are safe and effe...

Read More

MEDICAL

PFIZER AND BIONTECH BEGIN ROLLING SUBMISSION OF BIOLOGICS LICENSE APPLICATION FOR FDA APPROVAL OF COVID-19 VACCINE IN THE U.S

Pfizer, BioNTech | May 10, 2021

news image

Pfizer Inc. and BioNTech SE confirmed today the filing of a Biologics License Application (BLA) with the US Food and Drug Administration (FDA) for approval of their mRNA vaccine to prevent COVID-19 in people aged 16 and above. Companies will send data to help the BLA to the FDA on a rolling basis in the coming weeks, along with a proposal for Priority Review. If the BLA has been completed and duly approved for review by the FDA, the FDA will set a target date for a determination under the Prescr...

Read More

CELL AND GENE THERAPY

MERCK ENTERS INTO OUT-LICENSING AGREEMENT WITH BIOTECHNOLOGY COMPANY VERA THERAPEUTICS

Merck | November 11, 2020

news image

Merck, a leading science and technology company, today announced that it, through its subsidiary Ares Trading S.A., has entered into an out-licensing agreement with biotechnology company Vera Therapeutics, South San Francisco, USA, for the further development of investigational therapy atacicept. Vera Therapeutics will first prioritize to take atacicept into a Phase IIb study in IgA nephropathy (IgAN), an autoimmune kidney disease also known as "Berger's disease". "The positiv...

Read More

HALO LABS LAUNCHED AGGREGATE AND PARTICLE ID, CALLED AURA FOR BIOTHERAPEUTIC DEVELOPMENT

Halo Labs | June 29, 2020

news image

Halo Labs, a life science instrumentation company developing tools for biologics researchers, today announced it has launched its latest aggregate and particle identification system, called Aura™.Aura is the next generation of the Horizon®, Halo Labs' popular Backgrounded Membrane Imaging (BMI) platform. With as little as 5 µL and a linear range of over 3x106 particles/mL, BMI can count, size, and image aggregates and particles in the subvisible range (>1 μm). The...

Read More
news image

MEDTECH

OCHRE BIO ENTERS INTO CHARITABLE DONATION AGREEMENT WITH BRITISH LIVER TRUST

Ochre Bio | December 15, 2021

Ochre Bio, a biotech company developing RNA medicines for chronic liver diseases, announced to have entered into a Charitable Donation Agreement with the British Liver Trust in support of improving awareness for liver health. “On our path to develop next-generation RNA medicines with the potential to improve the lives of patients in need of a liver transplant, we are grateful to have access to discarded donor livers, allowing us to develop therapeutics that are safe and effe...

Read More
news image

MEDICAL

PFIZER AND BIONTECH BEGIN ROLLING SUBMISSION OF BIOLOGICS LICENSE APPLICATION FOR FDA APPROVAL OF COVID-19 VACCINE IN THE U.S

Pfizer, BioNTech | May 10, 2021

Pfizer Inc. and BioNTech SE confirmed today the filing of a Biologics License Application (BLA) with the US Food and Drug Administration (FDA) for approval of their mRNA vaccine to prevent COVID-19 in people aged 16 and above. Companies will send data to help the BLA to the FDA on a rolling basis in the coming weeks, along with a proposal for Priority Review. If the BLA has been completed and duly approved for review by the FDA, the FDA will set a target date for a determination under the Prescr...

Read More
news image

CELL AND GENE THERAPY

MERCK ENTERS INTO OUT-LICENSING AGREEMENT WITH BIOTECHNOLOGY COMPANY VERA THERAPEUTICS

Merck | November 11, 2020

Merck, a leading science and technology company, today announced that it, through its subsidiary Ares Trading S.A., has entered into an out-licensing agreement with biotechnology company Vera Therapeutics, South San Francisco, USA, for the further development of investigational therapy atacicept. Vera Therapeutics will first prioritize to take atacicept into a Phase IIb study in IgA nephropathy (IgAN), an autoimmune kidney disease also known as "Berger's disease". "The positiv...

Read More
news image

HALO LABS LAUNCHED AGGREGATE AND PARTICLE ID, CALLED AURA FOR BIOTHERAPEUTIC DEVELOPMENT

Halo Labs | June 29, 2020

Halo Labs, a life science instrumentation company developing tools for biologics researchers, today announced it has launched its latest aggregate and particle identification system, called Aura™.Aura is the next generation of the Horizon®, Halo Labs' popular Backgrounded Membrane Imaging (BMI) platform. With as little as 5 µL and a linear range of over 3x106 particles/mL, BMI can count, size, and image aggregates and particles in the subvisible range (>1 μm). The...

Read More